Emilie Vannier-Allard - Publications

Recent advances in nanomaterial delivery systems to administer metformin for cancer therapy.

Journal: Nanomedicine : nanotechnology, biology, and medicine

Published: March 05, 2026

Hospital in-use evaluation of the physical, chemical and affinity stability of the antibody-drug conjugate trastuzumab deruxtecan (Enhertu®).

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: February 13, 2026

Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer.

Journal: Journal of medicinal chemistry

Published: September 05, 2025

Development of anti-EGFR targeted magnetic nanoparticles for doxorubicin delivery into triple negative breast cancer cells.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: June 19, 2025

Metformin-encapsulating immunoliposomes conjugated with anti-TROP 2 antibody fragments for the active targeting of triple-negative breast cancer.

Journal: Nanoscale

Published: January 08, 2025

Design, optimization, characterization, and in vitro evaluation of metformin-loaded liposomes for triple negative breast cancer treatment.

Journal: Journal of liposome research

Published: March 09, 2024

Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: July 21, 2023

In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model.

Journal: International journal of pharmaceutics: X

Published: November 24, 2022

Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines.

Journal: Pharmaceutics

Published: October 20, 2022

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells.

Journal: Pharmaceutics

Published: October 15, 2022

Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: September 16, 2022

Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.

Journal: International journal of pharmaceutics: X

Published: August 30, 2022